Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Personalizing busulfan-based conditioning: considerations from the american society for blood and marrow transplantation practice guidelines committee
Abstract The Practice Guidelines Committee of the American Society of Blood or Marrow
Transplantation (ASBMT) sought to develop an evidence-based review about personalizing …
Transplantation (ASBMT) sought to develop an evidence-based review about personalizing …
A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow …
V Domingos, K Nezvalova-Henriksen… - Bone Marrow …, 2024 - nature.com
Busulfan (Bu) is an important component of many conditioning regimens for allogeneic
hematopoietic cell transplantation. The therapeutic window of Bu is well characterized, with …
hematopoietic cell transplantation. The therapeutic window of Bu is well characterized, with …
[HTML][HTML] Once daily iv busulfan and fludarabine (iv Bu-Flu) compares favorably with iv busulfan and cyclophosphamide (iv BuCy2) as pretransplant conditioning …
We postulated that fludarabine (Flu) instead of cyclophosphamide (Cy) combined with iv
busulfan (Bu) as preconditioning for allogeneic hematopoietic stem cell transplantation …
busulfan (Bu) as preconditioning for allogeneic hematopoietic stem cell transplantation …
Therapeutic drug monitoring of busulfan in transplantation
JA Russell, SB Kangarloo - Current pharmaceutical design, 2008 - ingentaconnect.com
Busulfan is the only agent used in myeloablative regimens for hematopoietic stem cell
transplantation for which therapeutic drug monitoring (TDM) has been widely used. Studies …
transplantation for which therapeutic drug monitoring (TDM) has been widely used. Studies …
[HTML][HTML] Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell …
T Schechter, Y Finkelstein, J Doyle, Z Verjee… - Biology of Blood and …, 2007 - Elsevier
We conducted a retrospective pharmacokinetic analysis of iv busulfan in children
undergoing hematopoietic stem cell transplantation (HSCT) and describe its relation to …
undergoing hematopoietic stem cell transplantation (HSCT) and describe its relation to …
Once-daily iv BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and …
J Yin, Y **ao, H Zheng, YC Zhang - Bone marrow transplantation, 2015 - nature.com
Iv BU has been proven to have better bioavailability, reliable systemic drug exposure with
more predictable blood levels and lower toxicity than oral BU when used as part of …
more predictable blood levels and lower toxicity than oral BU when used as part of …
Reduced‐toxicity conditioning with fludarabine, once‐daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a …
BACKGROUND The optimal intensity of myeloablation delivered as part of a reduced‐
intensity/toxicity conditioning (RIC/RTC) regimen to decrease the recurrence rate, without …
intensity/toxicity conditioning (RIC/RTC) regimen to decrease the recurrence rate, without …
Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring
C Ellen Nath, P John Shaw - Current clinical pharmacology, 2007 - ingentaconnect.com
Busulphan (Bu) is an alkylating agent that, when combined with agents such as
cyclophosphamide (Cy), ablates the bone marrow prior to blood or marrow transplantation …
cyclophosphamide (Cy), ablates the bone marrow prior to blood or marrow transplantation …
Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients
CE Nath, JW Earl, N Pati, K Stephen… - British journal of …, 2008 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The pharmacokinetics of oral
busulphan given four times daily has been extensively studied.• Large inter‐and …
busulphan given four times daily has been extensively studied.• Large inter‐and …
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid …
Pre‐transplant minimal residual disease (MRD) impacts negatively on post‐transplant
relapse risk in acute myeloid leukemia (AML). Therapeutic drug monitoring by calculating …
relapse risk in acute myeloid leukemia (AML). Therapeutic drug monitoring by calculating …